Hormozgan University of Medical Sciences   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bandar Abbas Iran (Islamic Republic of) (1983)

Organization Overview

First Clinical Trial
2007
NCT01305317
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Aida Najafian | Hamidreza Mahboobi | Hormozgan University of Medical Science (HUMS) | Hormozgan University of Medical Sciences | Hormozgan University of Medical Sciences (HUMS) | Hormzgan University of Medical Sciences (HUMS)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiac Complexes, Premature (Phase 4)

Cerebral Palsy (Phase 2)

Enuresis (Phase 3)

Femoral Fractures (Phase 3)

Fetal Death (Phase 2)

Fetal Membranes, Premature Rupture (Phase 2)

Fractures, Bone (Phase 3)

Hemorrhage (Phase 1)

Hyperbilirubinemia (Phase 3)

Hyperbilirubinemia, Neonatal (Phase 3)

Muscle Spasticity (Phase 2)

Neonatal Sepsis (Phase 3)

Nocturnal Enuresis (Phase 3)

Otitis (Phase 3)

Otitis Media (Phase 3)

Otitis Media with Effusion (Phase 3)

Pneumonia (Phase 4)

Postpartum Hemorrhage (Phase 1)

Pre-Eclampsia (Phase 2)

Pregnancy, Ectopic (Phase 4)

Rupture (Phase 2)

Sepsis (Phase 3)

Toxemia (Phase 3)

Urinary Incontinence (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 25